Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Price | Value | Graham Fair Value | Graham Fair Value % | P/E | Forward P/E | P/S | P/B | PEG | Free Cash Flow | Free Cash Flow Yield | Book Value | BVPS | EV | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONC | BEONE MEDICINES LTD | $376.63 | $7.19 | 5,134.92% | 7,532.60x | 362.11x | 8.35x | 10.10x | 20.14x | $529.27M | 1.28% | $4.13B | 37.48 | $39.59B | 124.48 | ||
| CORT | CORCEPT THERAPEUTICS INC | $75.12 | $32.31 | 132.50% | 75.12x | 73.83x | 10.49x | 12.50x | 1.05x | $162.57M | 2.09% | $631.90M | 6.10 | $7.78B | 117.96 | ||
| NVO | NOVO NORDISK A S | $48.46 | $149.69 | -67.63% | 13.48x | 2.03x | 4.43x | 8.23x | 0.14x | $9.34B | 4.34% | $26.18B | 5.89 | $225.98B | 9.11 | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $460.54 | $28.68 | 1,505.54% | 1,485.61x | 316.33x | 18.86x | 260.13x | 6.32x | $221.36M | 0.37% | $233.89M | 1.78 | $62.57B | 411.83 | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $2.22 | $4.94 | -55.09% | 31.71x | 16.91x | 2.85x | 3.37x | 0.18x | -$11.69M | -6.62% | $52.91M | 0.67 | $173.07M | 19.51 | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $9.18 | $11.18 | -17.90% | 19.13x | 7.48x | 6.09x | 3.88x | 0.40x | -$23.64M | -4.61% | $133.17M | 2.38 | $525.09M | 7.81 | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $41.40 | $14.96 | 176.81% | 84.49x | 39.12x | 5.17x | 5.86x | 1.26x | $101.73M | 3.29% | $535.38M | 7.17 | $2.97B | 55.49 | ||
| LGND | LIGAND PHARMACEUTICALS INC | $201.35 | $60.86 | 230.87% | 87.16x | 28.75x | 15.69x | 4.17x | 1.57x | $30.76M | 0.78% | $950.17M | 48.53 | $4.27B | 41.49 | ||
| VCEL | VERICEL CORP | $39.43 | $7.20 | 447.39% | 151.65x | 175.71x | 7.70x | 6.20x | 2.55x | $20.38M | 1.02% | $321.86M | 6.38 | $1.99B | 67.95 | ||
| ARGX | ARGENX SE | $929.61 | $255.21 | 264.25% | 37.15x | 55.55x | 29,987.42x | 7.91x | 3.11x | $467.72M | 0.82% | $7.17B | 117.50 | $54.33B | 66.97 | ||
| GMAB | GENMAB A | $30.42 | $113.37 | -73.17% | 12.98x | 1.75x | 5.48x | 3.40x | 0.11x | $1.19B | 6.11% | $5.75B | 8.96 | $17.91B | 8.95 | ||
| KRYS | KRYSTAL BIOTECH INC | $208.25 | $83.19 | 150.34% | 30.18x | 40.88x | 16.16x | 5.31x | 1.78x | $166.02M | 2.75% | $1.14B | 39.30 | $5.66B | 29.26 | ||
| TECH | BIO-TECHNE CORP | $58.61 | $16.10 | 264.14% | 117.22x | 28.68x | 7.49x | 4.65x | 1.64x | $224.06M | 2.46% | $1.97B | 12.65 | $9.38B | 42.47 | ||
| RPRX | ROYALTY PHARMA PLC | $39.16 | $41.27 | -5.10% | 22.25x | 8.55x | 7.20x | 2.35x | 0.47x | $2.11B | 12.48% | $9.62B | 22.28 | $30.61B | 29.32 | ||
| VCYT | VERACYTE INC | $39.28 | $8.81 | 345.90% | 100.72x | 98.32x | 6.25x | 2.47x | 2.21x | $98.21M | 3.18% | $1.26B | 15.98 | $2.83B | 49.62 | ||
| CRMD | CORMEDIX INC | $9.98 | $16.46 | -39.36% | 4.40x | 4.71x | 3.54x | 2.10x | 1.11x | $74.42M | 9.82% | $374.13M | 4.93 | $886.74M | 7.90 | ||
| HALO | HALOZYME THERAPEUTICS INC | $70.56 | $76.14 | -7.33% | 14.43x | 11.24x | 6.65x | 16.47x | 0.54x | $602.40M | 7.28% | $503.92M | 4.30 | $9.39B | 11.10 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $54.46 | $41.54 | 31.11% | 20.02x | 17.93x | 3.38x | 1.73x | 0.78x | $832.13M | 7.96% | $6.06B | 31.54 | $9.81B | 12.69 | ||
| GYRE | GYRE THERAPEUTICS INC | $8.02 | $0.85 | 848.65% | 114.57x | 76.09x | 6.79x | 7.58x | 6.73x | $3.05M | 0.42% | $101.92M | 1.12 | $733.35M | 55.44 | ||
| MDXG | MIMEDX GROUP INC | $7.10 | $3.58 | 98.39% | 25.36x | 16.38x | 2.67x | 4.40x | 1.34x | $66.82M | 6.35% | $238.95M | 1.61 | $927.66M | 13.40 | ||
| EXEL | EXELIXIS INC | $42.42 | $26.99 | 57.17% | 17.24x | 17.70x | 4.98x | 5.26x | 1.23x | $779.77M | 6.85% | $2.16B | 8.05 | $11.17B | 12.05 | ||
| INVA | INNOVIVA INC | $21.97 | $18.02 | 21.90% | 11.62x | 18.46x | 3.91x | 1.63x | 1.15x | $196.54M | 12.95% | $1.01B | 14.63 | $1.42B | 6.63 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $33.99 | $39.28 | -13.47% | 10.52x | 10.40x | 2.37x | 2.34x | 0.61x | $296.89M | 15.18% | $835.12M | 14.51 | $1.48B | 5.49 | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $434.02 | $171.26 | 153.43% | 30.33x | 23.61x | 9.46x | 6.36x | 1.81x | $3.34B | 3.01% | $17.32B | 67.76 | $107.01B | 22.95 | ||
| AUPH | AURINIA PHARMACEUTICALS INC | $15.49 | $7.07 | 119.16% | 26.71x | 23.42x | 7.68x | 5.58x | 1.54x | $119.87M | 5.87% | $365.77M | 2.78 | $2.05B | 19.78 | ||
| ADMA | ADMA BIOLOGICS INC | $15.42 | $9.20 | 67.53% | 17.52x | 25.48x | 7.53x | 8.51x | 1.39x | $40.73M | 1.11% | $431.19M | 1.81 | $3.68B | 21.39 | ||
| INCY | INCYTE CORP | $104.17 | $66.32 | 57.08% | 17.25x | 14.95x | 4.23x | 4.40x | 1.23x | $1.20B | 5.87% | $4.65B | 23.77 | $18.03B | 10.72 | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $22.56 | $10.75 | 109.77% | 12.60x | 15.17x | 4.78x | 3.01x | 21.28x | $234.54M | 8.48% | $920.25M | 7.51 | $2.09B | 6.44 | ||
| MNKD | MANNKIND CORP | $4.98 | $1.26 | 293.80% | 49.80x | 52.59x | 4.87x | -34.32x | 2.68x | $43.39M | 2.83% | -$44.55M | -0.15 | $1.76B | 24.07 | ||
| UTHR | UNITED THERAPEUTICS CORP | $471.92 | $192.09 | 145.68% | 16.57x | 16.81x | 6.61x | 3.08x | 6.40x | $1.12B | 5.43% | $6.59B | 150.46 | $18.98B | 10.70 | ||
| REGN | REGENERON PHARMACEUTICALS INC | $704.31 | $346.42 | 103.31% | 16.21x | 16.47x | 5.12x | 2.39x | 2.74x | $4.22B | 5.79% | $30.96B | 298.82 | $74.22B | 12.99 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.